SEP 12, 2021 4:44 AM PDT

Real-World, Post-Delta COVID-19 Vaccine Data & Potential Treatment

WRITTEN BY: Carmen Leitch

Recent work has confirmed that the vaccines developed by Pfizer, Moderna, and Johnson & Johnson are effective at preventing SARS-CoV-2 infection, which causes COVID-19. Researchers analyzed data collected in the United States from June, July, and August 2021, after the Delta variant became the dominant cause of SARS-CoV-2 infections in the country; 32,000 medical encounters were included in this study. The research found that among people who get COVID-19, those who have not been vaccinated are five to seven times more likely to need emergency care than vaccinated people.

Image credit: Cropped from a colorized scanning electron micrograph of a cell (red) infected with a variant strain of SARS-CoV-2 virus particles (green), isolated from a patient sample. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Courtesy: NIAID

The Moderna vaccine was found to be 95 percent effective at preventing hospitalizations due to COVID-19 in people over age 18, and 92 percent effective at preventing urgent or emergency care visits. For the Pfizer vaccine, 80 percent of hospitalizations and 77 percent of urgent or emergency care visits are prevented, and for the Johnson & Johnson vaccine, 60 percent of hospitalizations and 65 percent of urgent or emergency clinic visits are prevented.

“Despite the differences in effectiveness, vaccines continue to offer much more protection than not getting one at all,” noted Shaun Grannis, M.D., M.S., Regenstrief Institute vice president for data and analytics. “While breakthrough cases do happen, data shows the symptoms are less severe. The vast majority of COVID hospitalizations and deaths continue to be among unvaccinated individuals. COVID-19 vaccines are powerful tools for combating the pandemic.”

Over 176 million Americans have been vaccinated for COVID-19 as of September 7, 2021. Up to this point, the CDC has recorded about 2,000 deaths from breakthrough infections, the term for a SARS-CoV-2 infection in a vaccinated person. Most of those individuals have been over the age of 80.

Researchers are also continuing to search for an effective treatment for COVID-19. Scientists have used a variety of methods to screen existing drugs for potential candidates. New research reported in Nature has suggested that Probenecid may work as a preventive medication or post-exposure treatment. The study showed that it was able to stop the virus from replicating in animal models of both influenza and SARS-CoV-2 infection. Probenecid is already FDA-approved and has been on the market for over 40 years. It is typically used as a gout treatment and doesn't have many side effects.

“There’s really nothing out there to safely fight these viruses,” said lead Nature study author Ralph Tripp, GRA Eminent Scholar of Vaccine and Therapeutic Studies in UGA’s College of Veterinary Medicine. “This antiviral works for all RNA respiratory viruses we tested, including SARS-CoV-2. RSV, coronavirus, and flu all circulate in the same season. Bottom line is you can potentially reduce infection and disease using this one oral drug,"

Sources: Regenstrief Institute, University of Georgia, MMWR Morbidity and Mortality Weekly Report, Nature

About the Author
  • Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
APR 16, 2021
Coronavirus
Stressing the Importance of Acknowledging Airborne COVID-19 Transmission
APR 16, 2021
Stressing the Importance of Acknowledging Airborne COVID-19 Transmission
For months, officials have been debating whether the pandemic virus that causes COVID-19, SARS-CoV-2, is airborne. Resea ...
MAY 14, 2021
Coronavirus
How COVID-19 Patients Lose Their Sense of Smell
MAY 14, 2021
How COVID-19 Patients Lose Their Sense of Smell
The loss of the sense of smell is a well-known symptom of COVID-19, and was common even in people that did not have many ...
JUL 18, 2021
Drug Discovery & Development
COVID-19 Antibiotic No More Effective than Placebo
JUL 18, 2021
COVID-19 Antibiotic No More Effective than Placebo
Azithromycin, a broad-spectrum antibiotic commonly used to prevent symptoms of COVID-19 in non-hospitalized patients, do ...
JUL 28, 2021
Technology
Addressing The Environmental Impact Of Disposable Masks
JUL 28, 2021
Addressing The Environmental Impact Of Disposable Masks
At the height of the COVID-19 pandemic, mask wearing was a regular part of life as governments imposed mandates to help ...
AUG 26, 2021
Coronavirus
Researchers View COVID-19 Progression in a Live Animal Model
AUG 26, 2021
Researchers View COVID-19 Progression in a Live Animal Model
Scientists have used a mouse model to visualize the progression of a SARS-CoV-2 infection as it led to sometimes fatal c ...
SEP 14, 2021
Health & Medicine
Graphene-Oxide Based Nanotechnology and Immunology-An Exciting Partnership
SEP 14, 2021
Graphene-Oxide Based Nanotechnology and Immunology-An Exciting Partnership
As treatments and infection control practices surrounding COVID-19 continue to evolve, nanotechnological solutions are b ...
Loading Comments...